[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571912":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":36,"locations":46,"responsibleParty":192,"collaborators":35,"id":195,"slug":196,"hasResults":197,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":197,"sex":203,"minAge":204,"maxAge":35,"enrollmentInfo":205,"targetDuration":35,"studyType":208,"phases":209,"briefSummary":211,"conditions":212,"keywords":216,"overallStatus":49,"whyStopped":35,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":231},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT arm","EXPERIMENTAL","Patients undergo SBRT to all metastatic sites in addition to standard systemic therapy. Patients should complete radiotherapy for all lesions within 6 months of enrollment, preferably within the first 3 months.",[13,14],"Radiation: Stereotactic body radiotherapy (SBRT)","Drug: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib",{"label":16,"type":17,"description":18,"interventionNames":19},"Control arm","ACTIVE_COMPARATOR","Patients receive standard systemic therapy.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Stereotactic body radiotherapy (SBRT)","The preferred treatment plan is SBRT with a fraction dose ≥7 Gy. The prescription dose should ensure a BED of no less than 115. Radiotherapy is usually delivered daily, every other day, or other interval decided by treating radiation oncologist.",[9],[27],"Stereotactic ablative radiotherapy",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib","Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.",[16,9],[34],"Standard systemic therapy",null,[37,42],{"name":38,"role":39,"phone":40,"phoneExt":35,"email":41},"Liru He, PhD","CONTACT","0086-13631365597","helir@wy.sysucc.org.cn",{"name":43,"role":39,"phone":44,"phoneExt":35,"email":45},"Fangjian Zhou, PhD","0086-13922735659","zhoufj@wy.sysucc.org.cn",[47,65,80,94,108,126,140,160,175],{"facility":48,"status":49,"city":50,"state":51,"zip":35,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Union Hospital, Fujian Medical University","RECRUITING","Fuzhou","Fujian","China","CN",{"type":55,"coordinates":56},"Point",[57,58],119.30611,26.06139,{"lat":58,"lon":57},[61],{"name":62,"role":39,"phone":63,"phoneExt":35,"email":64},"Jianhui Chen","+8659183357896","chenjianhui1983@qq.com",{"facility":66,"status":49,"city":67,"state":68,"zip":69,"country":52,"countryCode":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Sun Yat-sen University Cancer Center","Guangzhou","Guangdong","510060",{"type":55,"coordinates":71},[72,73],113.25,23.11667,{"lat":73,"lon":72},[76,77,79],{"name":38,"role":39,"phone":40,"phoneExt":35,"email":41},{"name":43,"role":78,"phone":35,"phoneExt":35,"email":35},"PRINCIPAL_INVESTIGATOR",{"name":38,"role":78,"phone":35,"phoneExt":35,"email":35},{"facility":81,"status":49,"city":82,"state":83,"zip":35,"country":52,"countryCode":53,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei",{"type":55,"coordinates":85},[86,87],114.26667,30.58333,{"lat":87,"lon":86},[90],{"name":91,"role":39,"phone":92,"phoneExt":35,"email":93},"Fang Huang","+862785726114","2022XH0002@hust.edu.cn",{"facility":95,"status":49,"city":96,"state":97,"zip":35,"country":52,"countryCode":53,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"The First Hospital of Jilin University","Changchun","Jilin",{"type":55,"coordinates":99},[100,101],125.32278,43.88,{"lat":101,"lon":100},[104],{"name":105,"role":39,"phone":106,"phoneExt":35,"email":107},"Ziling Liu","+8643188782222","ziling@jlu.edu.cn",{"facility":109,"status":49,"city":110,"state":111,"zip":112,"country":52,"countryCode":53,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"West China Hospital, Sichuan University","Chengdu","Sichuan","610041",{"type":55,"coordinates":114},[115,116],104.06667,30.66667,{"lat":116,"lon":115},[119,123,124],{"name":120,"role":39,"phone":121,"phoneExt":35,"email":122},"Yali Shen","0086-18980605780","sylprecious@163.com",{"name":120,"role":78,"phone":35,"phoneExt":35,"email":35},{"name":125,"role":78,"phone":35,"phoneExt":35,"email":35},"Hao Zeng",{"facility":127,"status":49,"city":128,"state":129,"zip":35,"country":52,"countryCode":53,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"The First Affiliated Hospital of Wenzhou Medical University","Wenzhou","Zhejiang",{"type":55,"coordinates":131},[132,133],120.66682,27.99942,{"lat":133,"lon":132},[136],{"name":137,"role":39,"phone":138,"phoneExt":35,"email":139},"Hang Huang","+8657755578100","huanghang@wmu.edu.cn",{"facility":141,"status":142,"city":143,"state":35,"zip":144,"country":52,"countryCode":53,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Cancer Hospital, Chinese Academy of Medical Sciences","NOT_YET_RECRUITING","Beijing","100021",{"type":55,"coordinates":146},[147,148],116.39723,39.9075,{"lat":148,"lon":147},[151,155,157,158],{"name":152,"role":39,"phone":153,"phoneExt":35,"email":154},"Ningning Lu","0086-18611804268","ningninglu09@163.com",{"name":156,"role":78,"phone":35,"phoneExt":35,"email":35},"Yueping Liu",{"name":152,"role":78,"phone":35,"phoneExt":35,"email":35},{"name":159,"role":78,"phone":35,"phoneExt":35,"email":35},"Xiongjun Ye",{"facility":161,"status":49,"city":143,"state":35,"zip":162,"country":52,"countryCode":53,"cosmosGeoPoint":163,"geoPoint":165,"contacts":166},"Peking University First Hospital","100034",{"type":55,"coordinates":164},[147,148],{"lat":148,"lon":147},[167,171,173],{"name":168,"role":39,"phone":169,"phoneExt":35,"email":170},"Mingwei Ma","0086-15810160120","dr.mingweima@stu.pku.edu.cn",{"name":172,"role":78,"phone":35,"phoneExt":35,"email":35},"Xianshu Gao",{"name":174,"role":78,"phone":35,"phoneExt":35,"email":35},"Wei Yu",{"facility":176,"status":49,"city":177,"state":35,"zip":178,"country":52,"countryCode":53,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"Fudan University Shanghai Cancer Center","Shanghai","200032",{"type":55,"coordinates":180},[181,182],121.45806,31.22222,{"lat":182,"lon":181},[185,189,190],{"name":186,"role":39,"phone":187,"phoneExt":35,"email":188},"Xuejun Ma","0086-18017312303","chateauma@hotmail.com",{"name":186,"role":78,"phone":35,"phoneExt":35,"email":35},{"name":191,"role":78,"phone":35,"phoneExt":35,"email":35},"Hailiang Zhang",{"type":78,"investigatorFullName":193,"investigatorTitle":194,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"ZHOU FANGJIAN","Principal Investigator","100571912","phase-3-systemic-therapy-alone-or-with-stereotactic-body-radiotherapy-for-oligometastatic-kidney-cancer-stroker-study-100571912",false,"NCT06726421","Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","Systemic Therapy Combined With Radiotherapy Versus Systemic Therapy Alone for Oligometastatic Kidney CancER (STROKER): A Multicenter, Randomized Controlled Phase III Trial","STROKER","Inclusion Criteria:\n\n* Pathologically confirmed diagnosis of renal cell carcinoma of any histology\n* Age ≥ 18 years.\n* ECOG performance status of 0-2.\n* Imaging suggests the presence of distant metastases, with no more than 5 metastatic lesions according to RECIST 1.1 criteria and MDA standards.\n* The patient has received local therapy to primary site, including surgery, stereotactic radiotherapy, or ablation.\n* The patient has received no more than 2 lines of systemic therapy.\n* No significant impairment of major organ function:\n\nHemoglobin (HB) ≥ 80 g\u002FL Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL Platelets (PLT) ≥ 75 × 10⁹\u002FL Serum total bilirubin ≤ 1.5 × ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN\n\nExclusion Criteria:\n\n* Presence of intracranial metastases.\n* Target lesions have previously received high-dose irradiation with .\n* Target lesions are unsuitable for radiation therapy judged by treating radiation oncologist (e.g., lesions invading the gastrointestinal tract or penetrating the bronchus).\n* Uncontrollable metastatic pleural effusion or ascites.\n* Presence of other malignancies that have not been cured.\n* History of significant psychiatric disorders that impede understanding of informed consent and compliance with the study protocol.\n* Presence of other serious illnesses that may pose significant risks or affect radiation therapy.\n* Women who are pregnant, breastfeeding, or with plans for childbearing during the study.\n* Any other reasons deemed by the investigator to make the subject unsuitable for participation in the study.","ALL","18 Years",{"count":206,"type":207},252,"ESTIMATED","INTERVENTIONAL",[210],"PHASE3","This phase III randomized controlled trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) in oligometastatic renal cell carcinoma. The study aims to determine if the addition of SBRT to standard systemic therapy prolong survival compared to the standard systemic therapy alone. In addition, the study will explore the impact of this combined modality therapy on patients' toxicity and quality of life. The researchers will compare SBRT plus standard systemic therapy to standard systemic therapy alone, which is targeted agents and immunotherapy in this case, to determine if SBRT could prolong survival.",[213,214,215],"Renal Cell Carcinoma (Kidney Cancer)","Kidney Cancer Metastatic","Renal Cell Carcinoma Metastatic",[217,218,219,220,221],"radiotherapy","SBRT","SABR","oligometastatic","oligometastasis","2026-01-14",{"date":224,"type":225},"2026-01-15","ACTUAL",{"date":227,"type":225},"2024-09-18",{"date":229,"type":207},"2033-09-30",{"name":5,"class":6},9]